Biogen (BIIB) PT Lowered to $250 at Baird on Alzheimer's Failure

March 21, 2019 8:20 AM
Baird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $250.00 (from $348.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Hot Comments

Next Articles